

Torben A Kruse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3573719/publications.pdf>

Version: 2024-02-01

86
papers

4,078
citations

172386

29
h-index

128225

60
g-index

90
all docs

90
docs citations

90
times ranked

8662
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
2	Genomic profiling of a randomized trial of interferon- γ vs hydroxyurea in MPN reveals mutation-specific responses. <i>Blood Advances</i> , 2022, 6, 2107-2119.	2.5	26
3	Abstract P5-07-07: Mapping clonal evolution and tumor heterogeneity by whole exome sequencing of tissue and plasma circulating tumor DNA in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P5-07-07-P5-07-07.	0.4	0
4	Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 433-446.	2.7	8
5	Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review. <i>Gynecologic Oncology</i> , 2021, 161, 884-895.	0.6	12
6	OTEH-4. Deeper insight into intratumoral heterogeneity by MRI and PET-guided stereotactic biopsies from glioblastoma patients. <i>Neuro-Oncology Advances</i> , 2021, 3, ii11-ii11.	0.4	0
7	Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in <i>BRCA1</i> - and <i>BRCA2</i> -associated breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1388-1398.	2.9	11
8	Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast Cancer. <i>Cancers</i> , 2021, 13, 4907.	1.7	0
9	The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients. <i>Blood</i> , 2021, 138, 3589-3589.	0.6	0
10	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
11	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
12	Increased oxidative stress with substantial dysregulation of genes related to oxidative stress and DNA repair after laparoscopic colon cancer surgery. <i>Surgical Oncology</i> , 2020, 35, 71-78.	0.8	5
13	Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma. <i>Experimental Hematology</i> , 2020, 84, 7-18.e12.	0.2	7
14	Ruxolitinib and interferon- γ 2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. <i>Haematologica</i> , 2020, 105, 2262-2272.	1.7	67
15	The Optimal Sequencing Depth of Tumor Biopsies for Identifying Clonal Cell Populations. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 790-795.	1.2	2
16	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019, 40, 1557-1578.	1.1	102
17	CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3. <i>Oncogene</i> , 2019, 38, 4560-4573.	2.6	22
18	Molecular signature of different lesion types in the brain white matter of patients with progressive multiple sclerosis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 205.	2.4	61

#	ARTICLE	IF	CITATIONS
19	Subtypes in BRCA-mutated breast cancer. <i>Human Pathology</i> , 2019, 84, 192-201.	1.1	22
20	Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. <i>Journal of Gastroenterology</i> , 2019, 54, 108-121.	2.3	14
21	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. <i>Platelets</i> , 2019, 30, 206-212.	1.1	21
22	Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response. <i>Blood</i> , 2019, 134, 4202-4202.	0.6	1
23	Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 2978-2978.	0.6	6
24	Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 5396-5396.	0.6	1
25	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
26	Myeloproliferative Neoplasms in Danish Twins. <i>Acta Haematologica</i> , 2018, 139, 195-198.	0.7	8
27	Whole Blood Gene Expression Profiling in patients undergoing colon cancer surgery identifies differential expression of genes involved in immune surveillance, inflammation and carcinogenesis. <i>Surgical Oncology</i> , 2018, 27, 208-215.	0.8	10
28	The <i>BRCA1</i> c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. <i>Journal of Medical Genetics</i> , 2018, 55, 15-20.	1.5	50
29	Sorted peripheral blood cells identify <i>CALR</i> mutations in B- and T-lymphocytes. <i>Leukemia and Lymphoma</i> , 2018, 59, 973-977.	0.6	15
30	Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer. <i>Oncotarget</i> , 2018, 9, 9030-9042.	0.8	22
31	Safety and efficacy of combination therapy of interferon- α 2 and ruxolitinib in polycythemia vera and myelofibrosis. <i>Cancer Medicine</i> , 2018, 7, 3571-3581.	1.3	38
32	Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression. <i>PLoS ONE</i> , 2018, 13, e0189887.	1.1	24
33	The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms. <i>Blood</i> , 2018, 132, 4328-4328.	0.6	1
34	Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. <i>Blood</i> , 2018, 132, 580-580.	0.6	14
35	Interferon- α 2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN- α Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation. <i>Blood</i> , 2018, 132, 4326-4326.	0.6	3
36	Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms. <i>Blood</i> , 2018, 132, 5491-5491.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Genetic Evidence for Involvement of Human Endogenous Retrovirus Herv-Fc1 in the Pathogenesis of MPNs. <i>Blood</i> , 2018, 132, 5488-5488.	0.6	0
38	Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms. <i>Blood</i> , 2018, 132, 5490-5490.	0.6	3
39	Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer. <i>Blood</i> , 2018, 132, 3071-3071.	0.6	1
40	The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients. <i>Blood</i> , 2018, 132, 4327-4327.	0.6	0
41	Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence. <i>Scientific Reports</i> , 2017, 7, 43813.	1.6	24
42	The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. <i>Leukemia and Lymphoma</i> , 2017, 58, 1914-1921.	0.6	17
43	The gene expression and immunohistochemical timeâ€course of diphenylcyclopropenoneâ€induced contact allergy in healthy humans following repeated epicutaneous challenges. <i>Experimental Dermatology</i> , 2017, 26, 926-933.	1.4	7
44	Investigating a case of possible field cancerization in oral squamous cell carcinoma by the use of next-generation sequencing. <i>Oral Oncology</i> , 2017, 68, 74-80.	0.8	15
45	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
46	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
47	The subclonal structure and genomic evolution of oral squamous cell carcinoma revealed by ultra-deep sequencing. <i>Oncotarget</i> , 2017, 8, 16571-16580.	0.8	25
48	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	0.8	152
49	Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. <i>PLoS ONE</i> , 2017, 12, e0183620.	1.1	51
50	Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. <i>PLoS ONE</i> , 2016, 11, e0165336.	1.1	38
51	Myelinâ€specific <i>T</i> cells induce interleukinâ€1 beta expression in lesionâ€reactive microglialâ€like cells in zones of axonal degeneration. <i>Glia</i> , 2016, 64, 407-424.	2.5	28
52	Molecular Concordance Between Primary Breast Cancer and Matched Metastases. <i>Breast Journal</i> , 2016, 22, 420-430.	0.4	44
53	Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data. <i>PLoS ONE</i> , 2016, 11, e0151664.	1.1	144
54	A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. <i>PLoS ONE</i> , 2016, 11, e0161570.	1.1	6

#	ARTICLE	IF	CITATIONS
55	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
56	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
57	Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers. <i>Breast Cancer Research</i> , 2015, 17, 55.	2.2	49
58	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
59	Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
60	The microRNA-132/212 family fine-tunes multiple targets in Angiotensin II signalling in cardiac fibroblasts. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 1288-1297.	1.0	27
61	Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study. <i>Blood</i> , 2015, 126, 824-824.	0.6	14
62	Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis. <i>Oncotarget</i> , 2015, 6, 5634-5649.	0.8	42
63	The Impact of Interferon-alpha2 on HLA-Genes in Patients with Polycythemia Vera and Related Neoplasms. <i>Blood</i> , 2015, 126, 4097-4097.	0.6	0
64	Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression. <i>PLoS ONE</i> , 2014, 9, e112786.	1.1	59
65	Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation. <i>PLoS ONE</i> , 2014, 9, e85567.	1.1	13
66	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
67	Microarray-Based RNA Profiling of Breast Cancer: Batch Effect Removal Improves Cross-Platform Consistency. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	21
68	RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families. <i>BMC Medical Genomics</i> , 2014, 7, 9.	0.7	18
69	Human longevity and variation in DNA damage response and repair: study of the contribution of sub-processes using competitive gene-set analysis. <i>European Journal of Human Genetics</i> , 2014, 22, 1131-1136.	1.4	31
70	Use of next generation sequencing in head and neck squamous cell carcinomas: A review. <i>Oral Oncology</i> , 2014, 50, 1035-1040.	0.8	21
71	Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics. <i>Breast Cancer: Basic and Clinical Research</i> , 2014, 8, BCBCR.S18715.	0.6	71
72	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493

#	ARTICLE	IF	CITATIONS
73	Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling. PLoS ONE, 2013, 8, e64268.	1.1	89
74	Latent growth curve modeling of incomplete timecourse data in microarray gene expression studies. , 2012, , .		0
75	Increased Expression of Proteasome-Related Genes In Patients with Primary Myelofibrosis. Blood, 2010, 116, 4117-4117.	0.6	5
76	Enhanced Gene Expression of EZH2 In Patients with Primary Myelofibrosis. Blood, 2010, 116, 4118-4118.	0.6	0
77	Gene Expression Profiling with Principal Component Analysis Depicts the Biological Continuum From Essential Thrombocythemia Over Polycythemia Vera to Myelofibrosis. Blood, 2010, 116, 4115-4115.	0.6	0
78	Increased Gene Expression of Histone Deacetylases In Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Blood, 2010, 116, 4119-4119.	0.6	1
79	High Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule(CEACAM) 6 In Primary Myelofibrosis. Blood, 2010, 116, 4116-4116.	0.6	10
80	Feature Selection for Predicting Tumor Metastases in Microarray Experiments using Paired Design. Cancer Informatics, 2007, 3, 117693510700300.	0.9	7
81	Spotting and validation of a genome wide oligonucleotide chip with duplicate measurement of each gene. Biochemical and Biophysical Research Communications, 2006, 344, 1111-1120.	1.0	11
82	Search for a shared segment on chromosome 10q26 in patients with bipolar affective disorder or schizophrenia from the Faroe Islands. American Journal of Medical Genetics Part A, 2002, 114, 196-204.	2.4	34
83	Search for a shared segment on chromosome 10q26 in patients with bipolar affective disorder or schizophrenia from the Faroe Islands. American Journal of Medical Genetics Part A, 2002, 114, 196-204.	2.4	1
84	A new locus for Seckel syndrome on chromosome 18p11.31-q11.2. European Journal of Human Genetics, 2001, 9, 753-757.	1.4	54
85	Allergic rhinitis " a total genome-scan for susceptibility genes suggests a locus on chromosome 4q24-q27. European Journal of Human Genetics, 2001, 9, 945-952.	1.4	59
86	Familial Isolated Hyperparathyroidism as a Variant of Multiple Endocrine Neoplasia Type 1 in a Large Danish Pedigree1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 165-167.	1.8	74